Shifting incidence and survival of epithelial ovarian cancer (1995-2014): a SurvMark-2 study

Citadel J. Cabasag, Melina Arnold, Mark Rutherford, Jacques Ferlay, Aude Bardot, Eileen Morgan, John Butler, Dianne L O'Connell, Gregg Nelson, Claus Høgdall, Tine Schnack, Anna Gavin, Mark Elwood, Louise Hanna, Charlie Gourley, Prithwish De, Nathalie Saint-Jacques, Lina Steinrud Mørch, Ryan R Woods, Alon D. AltmanPeter Sykes, Paul A. Cohen, Orla McNally, Bjørn Møller, Paul Walsh, David S Morrison, Freddie Bray, Isabelle Soerjomataram

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Abstract The aim of the study is to provide a comprehensive assessment of incidence and survival trends of epithelial ovarian cancer (EOC) by histological subtype across seven high income countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the United Kingdom). Data on invasive EOC diagnosed in women aged 15-99?years during 1995-2014 were obtained from 20 cancer registries. Age standardized incidence rates and average annual percentage change were calculated by subtype for all ages and age groups (15-64 and 65-99?years). Net survival (NS) was estimated by subtype, age group, and 5-year period using Pohar-Perme estimator. Our findings showed marked increase in serous carcinoma incidence was observed between 1995-2014 among women aged 65-99?years with average annual increase ranging between 2.2% and 5.8%. We documented a marked decrease in the incidence of adenocarcinoma ?not otherwise specified? with estimates ranging between 4.4% and 7.4% in women aged 15-64?years and between 2.0% and 3.7% among the older age group. Improved survival, combining all EOC subtypes, was observed for all ages combined over the 20-year study period in all countries with 5-year NS absolute percent change ranging between 5.0 in Canada and 12.6 in Denmark. Several factors such as changes in guidelines and advancement in diagnostic tools may potentially influence the observed shift in histological subtypes and temporal trends. Progress in clinical management and treatment over the past decades potentially plays a role in the observed improvements in EOC survival. This article is protected by copyright. All rights reserved.
Original languageEnglish
Pages (from-to)1763-1777
Number of pages15
JournalInternational Journal of Cancer
Issue number9
Publication statusPublished - 1 May 2023


Dive into the research topics of 'Shifting incidence and survival of epithelial ovarian cancer (1995-2014): a SurvMark-2 study'. Together they form a unique fingerprint.

Cite this